U.S. markets closed

Tetra Bio-Pharma Inc. (JAM1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.1760-0.0022 (-1.23%)
At close: 8:00AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1782
Open0.1760
Bid0.0000 x 4074100
Ask0.0000 x 2558200
Day's Range0.1760 - 0.1760
52 Week Range0.0790 - 0.3525
Volume4,000
Avg. Volume24,321
Market Cap70.671M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Tetra Bio-Pharma Engages Christine Caron as Patient Partner
      PR Newswire

      Tetra Bio-Pharma Engages Christine Caron as Patient Partner

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.

    • Tetra Bio-Pharma Accelerates REBORN1© Trial
      CNW Group

      Tetra Bio-Pharma Accelerates REBORN1© Trial

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial.

    • Horizons ETFs Rebalances Marijuana-Focused Index Etfs
      CNW Group

      Horizons ETFs Rebalances Marijuana-Focused Index Etfs

      Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalances of the holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX) and the Horizons US Marijuana Index ETF ("HMUS":NEO).